http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 07:34:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TG+THERAPEUTICS%2C+INC.+++++For%3A+Jun+03/26595442.html si-local-file:///var/storage/secattach/20260603/26595442.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TG+THERAPEUTICS%2C+INC.+++++For%3A+Jun+03/26595442.html Wed, 03 Jun 2026 07:34:00 -0400 O.01689677 TGTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TG+THERAPEUTICS%2C+INC.+++++For%3A+Jun+03/26595442.html si-local-file:///var/storage/secattach/20260603/26595442.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TG+THERAPEUTICS%2C+INC.+++++For%3A+Jun+03/26595442.html Wed, 03 Jun 2026 07:34:00 -0400 O.01689677 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+reports+positive+Phase+1+subcutaneous+BRIUMVI+trial+results/26595421.html <p>TG Therapeutics Inc. (NASDAQ: TGTX) announced positive results from its Phase 1 clinical trial evaluating a subcutaneous formulation of BRIUMVI (ublituximab-xiiy) compared to the currently approved intravenous version for treating multiple sclerosis.</p> <p>The trial enrolled over 100 patients, with more than 80 receiving subcutaneous BRIUMVI across multiple dose levels. The subcutaneous formulation demonstrated bioavailability greater than 60% relative to intravenous administration, with pharmacokinetic modeling supporting quarterly dosing regimens currently being evaluated in Phase 3 trials.</p> <p>Treatment with subcutaneous BRIUMVI resulted in B-cell depletion consistent with intravenous BRIUMVI. Local injection-site reactions occurred in less than 5% of patients, while systemic injection-related reactions occurred http://www.streetinsider.com/FDA/TG+Therapeutics+reports+positive+Phase+1+subcutaneous+BRIUMVI+trial+results/26595421.html Wed, 03 Jun 2026 07:30:34 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+reports+positive+Phase+1+subcutaneous+BRIUMVI+trial+results/26595421.html <p>TG Therapeutics Inc. (NASDAQ: TGTX) announced positive results from its Phase 1 clinical trial evaluating a subcutaneous formulation of BRIUMVI (ublituximab-xiiy) compared to the currently approved intravenous version for treating multiple sclerosis.</p> <p>The trial enrolled over 100 patients, with more than 80 receiving subcutaneous BRIUMVI across multiple dose levels. The subcutaneous formulation demonstrated bioavailability greater than 60% relative to intravenous administration, with pharmacokinetic modeling supporting quarterly dosing regimens currently being evaluated in Phase 3 trials.</p> <p>Treatment with subcutaneous BRIUMVI resulted in B-cell depletion consistent with intravenous BRIUMVI. Local injection-site reactions occurred in less than 5% of patients, while systemic injection-related reactions occurred http://www.streetinsider.com/FDA/TG+Therapeutics+reports+positive+Phase+1+subcutaneous+BRIUMVI+trial+results/26595421.html Wed, 03 Jun 2026 07:30:34 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+reports+positive+Phase+1+subcutaneous+BRIUMVI+trial+results/26595421.html <p>TG Therapeutics Inc. (NASDAQ: TGTX) announced positive results from its Phase 1 clinical trial evaluating a subcutaneous formulation of BRIUMVI (ublituximab-xiiy) compared to the currently approved intravenous version for treating multiple sclerosis.</p> <p>The trial enrolled over 100 patients, with more than 80 receiving subcutaneous BRIUMVI across multiple dose levels. The subcutaneous formulation demonstrated bioavailability greater than 60% relative to intravenous administration, with pharmacokinetic modeling supporting quarterly dosing regimens currently being evaluated in Phase 3 trials.</p> <p>Treatment with subcutaneous BRIUMVI resulted in B-cell depletion consistent with intravenous BRIUMVI. Local injection-site reactions occurred in less than 5% of patients, while systemic injection-related reactions occurred http://www.streetinsider.com/FDA/TG+Therapeutics+reports+positive+Phase+1+subcutaneous+BRIUMVI+trial+results/26595421.html Wed, 03 Jun 2026 07:30:34 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+reports+positive+Phase+1+subcutaneous+BRIUMVI+trial+results/26595421.html <p>TG Therapeutics Inc. (NASDAQ: TGTX) announced positive results from its Phase 1 clinical trial evaluating a subcutaneous formulation of BRIUMVI (ublituximab-xiiy) compared to the currently approved intravenous version for treating multiple sclerosis.</p> <p>The trial enrolled over 100 patients, with more than 80 receiving subcutaneous BRIUMVI across multiple dose levels. The subcutaneous formulation demonstrated bioavailability greater than 60% relative to intravenous administration, with pharmacokinetic modeling supporting quarterly dosing regimens currently being evaluated in Phase 3 trials.</p> <p>Treatment with subcutaneous BRIUMVI resulted in B-cell depletion consistent with intravenous BRIUMVI. Local injection-site reactions occurred in less than 5% of patients, while systemic injection-related reactions occurred http://www.streetinsider.com/FDA/TG+Therapeutics+reports+positive+Phase+1+subcutaneous+BRIUMVI+trial+results/26595421.html Wed, 03 Jun 2026 07:30:34 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html <p><em>Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 </em></p> <p><em>Novel Investigational high concentration subcutaneous formulation of BRIUMVI was well-tolerated with no new safety signals observed</em></p> <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the “Company” or “TG Therapeutics”), today announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) as compared to IV BRIUMVI.</p> http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html Wed, 03 Jun 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html <p><em>Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 </em></p> <p><em>Novel Investigational high concentration subcutaneous formulation of BRIUMVI was well-tolerated with no new safety signals observed</em></p> <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the “Company” or “TG Therapeutics”), today announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) as compared to IV BRIUMVI.</p> http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html Wed, 03 Jun 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html <p><em>Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 </em></p> <p><em>Novel Investigational high concentration subcutaneous formulation of BRIUMVI was well-tolerated with no new safety signals observed</em></p> <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the “Company” or “TG Therapeutics”), today announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) as compared to IV BRIUMVI.</p> http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html Wed, 03 Jun 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html <p><em>Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 </em></p> <p><em>Novel Investigational high concentration subcutaneous formulation of BRIUMVI was well-tolerated with no new safety signals observed</em></p> <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the “Company” or “TG Therapeutics”), today announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) as compared to IV BRIUMVI.</p> http://www.streetinsider.com/Press+Releases/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html Wed, 03 Jun 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html <p><em>Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 </em></p> <p><em>Novel Investigational high concentration subcutaneous formulation of BRIUMVI was well-tolerated with no new safety signals observed</em></p> <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the “Company” or “TG Therapeutics”), today announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) as compared to IV BRIUMVI.</p> http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html Wed, 03 Jun 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html <p><em>Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 </em></p> <p><em>Novel Investigational high concentration subcutaneous formulation of BRIUMVI was well-tolerated with no new safety signals observed</em></p> <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the “Company” or “TG Therapeutics”), today announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) as compared to IV BRIUMVI.</p> http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html Wed, 03 Jun 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html <p><em>Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 </em></p> <p><em>Novel Investigational high concentration subcutaneous formulation of BRIUMVI was well-tolerated with no new safety signals observed</em></p> <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the “Company” or “TG Therapeutics”), today announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) as compared to IV BRIUMVI.</p> http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html Wed, 03 Jun 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html <p><em>Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 </em></p> <p><em>Novel Investigational high concentration subcutaneous formulation of BRIUMVI was well-tolerated with no new safety signals observed</em></p> <p>NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the “Company” or “TG Therapeutics”), today announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) as compared to IV BRIUMVI.</p> http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+Announces+Positive+Results+from+Phase+1+Trial+Evaluating+Subcutaneous+BRIUMVI%C2%AE+%28ublituximab-xiiy%29/26595409.html Wed, 03 Jun 2026 07:30:00 -0400 A.31066700 O.01689677 O.22422661 TGTX http://www.streetinsider.com/Press+Releases/TG+Therapeutics+to+Participate+in+the+Goldman+Sachs+47th+Annual+Healthcare+Conference/26587473.html <p>NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47th Annual Healthcare Conference, being held at the Loews Miami Beach Hotel, in Miami Beach, Florida on June 8-10, 2026. The fireside chat is scheduled to take place on Tuesday, June 9, 2026, at 2:00 PM ET.</p> <p>A live webcast of the fireside chat will be available on the Events page, located within the Investors &amp; Media section, of the Company’s website at <a target="_blank" http://www.streetinsider.com/Press+Releases/TG+Therapeutics+to+Participate+in+the+Goldman+Sachs+47th+Annual+Healthcare+Conference/26587473.html Tue, 02 Jun 2026 07:30:00 -0400 O.01689677 TGTX http://www.streetinsider.com/Press+Releases/TG+Therapeutics+to+Participate+in+the+Goldman+Sachs+47th+Annual+Healthcare+Conference/26587473.html <p>NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47th Annual Healthcare Conference, being held at the Loews Miami Beach Hotel, in Miami Beach, Florida on June 8-10, 2026. The fireside chat is scheduled to take place on Tuesday, June 9, 2026, at 2:00 PM ET.</p> <p>A live webcast of the fireside chat will be available on the Events page, located within the Investors &amp; Media section, of the Company’s website at <a target="_blank" http://www.streetinsider.com/Press+Releases/TG+Therapeutics+to+Participate+in+the+Goldman+Sachs+47th+Annual+Healthcare+Conference/26587473.html Tue, 02 Jun 2026 07:30:00 -0400 O.01689677 TGTX http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+to+Participate+in+the+Goldman+Sachs+47th+Annual+Healthcare+Conference/26587473.html <p>NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47th Annual Healthcare Conference, being held at the Loews Miami Beach Hotel, in Miami Beach, Florida on June 8-10, 2026. The fireside chat is scheduled to take place on Tuesday, June 9, 2026, at 2:00 PM ET.</p> <p>A live webcast of the fireside chat will be available on the Events page, located within the Investors &amp; Media section, of the Company’s website at <a target="_blank" http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+to+Participate+in+the+Goldman+Sachs+47th+Annual+Healthcare+Conference/26587473.html Tue, 02 Jun 2026 07:30:00 -0400 O.01689677 TGTX http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+to+Participate+in+the+Goldman+Sachs+47th+Annual+Healthcare+Conference/26587473.html <p>NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47th Annual Healthcare Conference, being held at the Loews Miami Beach Hotel, in Miami Beach, Florida on June 8-10, 2026. The fireside chat is scheduled to take place on Tuesday, June 9, 2026, at 2:00 PM ET.</p> <p>A live webcast of the fireside chat will be available on the Events page, located within the Investors &amp; Media section, of the Company’s website at <a target="_blank" http://www.streetinsider.com/Globe+Newswire/TG+Therapeutics+to+Participate+in+the+Goldman+Sachs+47th+Annual+Healthcare+Conference/26587473.html Tue, 02 Jun 2026 07:30:00 -0400 O.01689677 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html <p>TG Therapeutics Inc. (NASDAQ: TGTX) announced the publication of post-hoc analysis data from its Phase 3 ULTIMATE I and II trials evaluating BRIUMVI in treatment-naive patients with relapsing forms of multiple sclerosis. The data was published in Frontiers in Immunology.</p> <p>The pooled analysis examined patients who had not received prior disease-modifying therapy over 96 weeks of treatment. BRIUMVI reduced annualized relapse rate by 56.7% versus teriflunomide in treatment-naive patients, with rates of 0.081 compared to 0.188 respectively.</p> <p>In patients treated within three years of symptom onset, BRIUMVI reduced relapse rates by 61.0%, showing rates of 0.130 versus 0.334 for teriflunomide. The treatment http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html Mon, 01 Jun 2026 07:30:42 -0400 A.06822034 A.11608963 A.41792313 O.01689677 O.05010326 O.20026344 O.20297397 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html <p>TG Therapeutics Inc. (NASDAQ: TGTX) announced the publication of post-hoc analysis data from its Phase 3 ULTIMATE I and II trials evaluating BRIUMVI in treatment-naive patients with relapsing forms of multiple sclerosis. The data was published in Frontiers in Immunology.</p> <p>The pooled analysis examined patients who had not received prior disease-modifying therapy over 96 weeks of treatment. BRIUMVI reduced annualized relapse rate by 56.7% versus teriflunomide in treatment-naive patients, with rates of 0.081 compared to 0.188 respectively.</p> <p>In patients treated within three years of symptom onset, BRIUMVI reduced relapse rates by 61.0%, showing rates of 0.130 versus 0.334 for teriflunomide. The treatment http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html Mon, 01 Jun 2026 07:30:42 -0400 A.06822034 A.11608963 A.41792313 O.01689677 O.05010326 O.20026344 O.20297397 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html <p>TG Therapeutics Inc. (NASDAQ: TGTX) announced the publication of post-hoc analysis data from its Phase 3 ULTIMATE I and II trials evaluating BRIUMVI in treatment-naive patients with relapsing forms of multiple sclerosis. The data was published in Frontiers in Immunology.</p> <p>The pooled analysis examined patients who had not received prior disease-modifying therapy over 96 weeks of treatment. BRIUMVI reduced annualized relapse rate by 56.7% versus teriflunomide in treatment-naive patients, with rates of 0.081 compared to 0.188 respectively.</p> <p>In patients treated within three years of symptom onset, BRIUMVI reduced relapse rates by 61.0%, showing rates of 0.130 versus 0.334 for teriflunomide. The treatment http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html Mon, 01 Jun 2026 07:30:42 -0400 A.06822034 A.11608963 A.41792313 O.01689677 O.05010326 O.20026344 O.20297397 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html <p>TG Therapeutics Inc. (NASDAQ: TGTX) announced the publication of post-hoc analysis data from its Phase 3 ULTIMATE I and II trials evaluating BRIUMVI in treatment-naive patients with relapsing forms of multiple sclerosis. The data was published in Frontiers in Immunology.</p> <p>The pooled analysis examined patients who had not received prior disease-modifying therapy over 96 weeks of treatment. BRIUMVI reduced annualized relapse rate by 56.7% versus teriflunomide in treatment-naive patients, with rates of 0.081 compared to 0.188 respectively.</p> <p>In patients treated within three years of symptom onset, BRIUMVI reduced relapse rates by 61.0%, showing rates of 0.130 versus 0.334 for teriflunomide. The treatment http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html Mon, 01 Jun 2026 07:30:42 -0400 A.06822034 A.11608963 A.41792313 O.01689677 O.05010326 O.20026344 O.20297397 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html <p>TG Therapeutics Inc. (NASDAQ: TGTX) announced the publication of post-hoc analysis data from its Phase 3 ULTIMATE I and II trials evaluating BRIUMVI in treatment-naive patients with relapsing forms of multiple sclerosis. The data was published in Frontiers in Immunology.</p> <p>The pooled analysis examined patients who had not received prior disease-modifying therapy over 96 weeks of treatment. BRIUMVI reduced annualized relapse rate by 56.7% versus teriflunomide in treatment-naive patients, with rates of 0.081 compared to 0.188 respectively.</p> <p>In patients treated within three years of symptom onset, BRIUMVI reduced relapse rates by 61.0%, showing rates of 0.130 versus 0.334 for teriflunomide. The treatment http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html Mon, 01 Jun 2026 07:30:42 -0400 A.06822034 A.11608963 A.41792313 O.01689677 O.05010326 O.20026344 O.20297397 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html <p>TG Therapeutics Inc. (NASDAQ: TGTX) announced the publication of post-hoc analysis data from its Phase 3 ULTIMATE I and II trials evaluating BRIUMVI in treatment-naive patients with relapsing forms of multiple sclerosis. The data was published in Frontiers in Immunology.</p> <p>The pooled analysis examined patients who had not received prior disease-modifying therapy over 96 weeks of treatment. BRIUMVI reduced annualized relapse rate by 56.7% versus teriflunomide in treatment-naive patients, with rates of 0.081 compared to 0.188 respectively.</p> <p>In patients treated within three years of symptom onset, BRIUMVI reduced relapse rates by 61.0%, showing rates of 0.130 versus 0.334 for teriflunomide. The treatment http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html Mon, 01 Jun 2026 07:30:42 -0400 A.06822034 A.11608963 A.41792313 O.01689677 O.05010326 O.20026344 O.20297397 TGTX http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html <p>TG Therapeutics Inc. (NASDAQ: TGTX) announced the publication of post-hoc analysis data from its Phase 3 ULTIMATE I and II trials evaluating BRIUMVI in treatment-naive patients with relapsing forms of multiple sclerosis. The data was published in Frontiers in Immunology.</p> <p>The pooled analysis examined patients who had not received prior disease-modifying therapy over 96 weeks of treatment. BRIUMVI reduced annualized relapse rate by 56.7% versus teriflunomide in treatment-naive patients, with rates of 0.081 compared to 0.188 respectively.</p> <p>In patients treated within three years of symptom onset, BRIUMVI reduced relapse rates by 61.0%, showing rates of 0.130 versus 0.334 for teriflunomide. The treatment http://www.streetinsider.com/FDA/TG+Therapeutics+publishes+data+showing+BRIUMVI+reduced+MS+relapses+by+56.7%25/26579238.html Mon, 01 Jun 2026 07:30:42 -0400 A.06822034 A.11608963 A.41792313 O.01689677 O.05010326 O.20026344 O.20297397 TGTX